FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200628818> ?p ?o ?g. }

• W4200628818 endingPage "104" @default.
• W4200628818 startingPage "87" @default.
• W4200628818 abstract "Phenazepam is commonly administered to patients diagnosed with major depressive disorder. Some proportion of such patients do not show adequate response to treatment regimen containing phenazepam, whereas many of them experience type A adverse drug reactions. Previous studies showed that CYP2D6 IS involved in the biotransformation of phenazepam, the activity of which is highly dependent on the polymorphism of the gene encoding it. Objective. The objective of the study was to evaluate the impact of 1846G>A polymorphism of the CYP2D6 gene on the concentration/dose indicator of phenazepam, using findings on enzymatic activity of CYP2D6 (as evaluated by the 6M-THBC/pinoline ratio measurement) and on CYP2D6 expression level obtained by measuring the hsa-miR-370-3p plasma concentration levels in patients suffering from major depressive disorder.The study enrolled 191 patients with recurrent depressive disorder (age -40.0 ± 16.3 years). Treatment regimen included phenazepam in an average daily dose of 6.0 ± 2.3 mg per day. Treatment efficacy was assessed using the validated psychometric scales. Therapy safety was assessed using the UKU Side-Effect Rating Scale. For genotyping and estimation of the microRNA (miRNA) plasma levels we performed the real-time polymerase chain reaction (PCR Real-time). The activity of CYP2D6 was evaluated using the HPLC-MS/MS method by the content of the endogenous substrate of given isoenzyme and its metabolite in urine (6M-THBC/pinoline). Therapeutic drug monitoring has been performed using HPLC-MS/MS.Our findings didn't reveal the statistically significant results in terms of the treatment efficacy evaluation (HAMA scores at the end of the treatment course): (GG) 6.0 [4.0; 8.0] and (GA) 6.0 [5.0; 7.8], p > 0.999; the statistical significance in the safety profile was not obtained (the UKU scores): (GG) 3.0 [2.0; 4.0] and (GA) 3.0 [3.0; 3.0], p > 0.999. We didn't reveal a statistical significance for concentration/dose indicator of phenazepam in patients with different genotypes: (GG) 0.812 [0.558; 1.348] and (GA) 0.931 [0.630; 1.271], p = 0.645). Analysis of the results of the pharmacotranscriptomic part of the study didn't show the statistically significant difference in the hsa-miR-370-3p plasma levels in patients with different genotypes: (GG) 22.5 [16.9; 29.8], (GA) 22.7 [15.7; 31.5], p = 0.695. At the same time, correlation analysis didn't reveal a statistically significant relationship between the phenazepam efficacy profile evaluated by changes in HAMA scale scores and the hsa-miR-370-3p plasma concentration: rs = -0.01, p = 0.866. Also, we didn't reveal the correlation between the miRNA concentration and safety profile: rs = 0.07, p = 0.348. Also we did not reveal the relationship between the CYP2D6 enzymatic activity (as evaluated by 6M-THBC/pinoline ratio measurement) and the hsa-miR-370-3p plasma concentration: rs = -0.14, p = 0.056. At the same time, correlation analysis did not reveal a statistically significant relationship between the phenazepam concentration and the hsa-miR-370-3p plasma concentration: rs = -0.05, p = 0.468.The effect of genetic polymorphism of the CYP2D6 gene on the efficacy and safety profiles of phenazepam was not demonstrated in a group of 191 patients with recurrent depressive disorder. At the same time, hsa-miR-370-3p does not remain a promising biomarker for assessing the level of CYP2D6 expression, because it does not correlate with encoded isoenzyme activity." @default.
• W4200628818 created "2021-12-31" @default.
• W4200628818 creator A5010764677 @default.
• W4200628818 creator A5016233102 @default.
• W4200628818 creator A5024470067 @default.
• W4200628818 creator A5025311833 @default.
• W4200628818 creator A5026059232 @default.
• W4200628818 creator A5039886441 @default.
• W4200628818 creator A5040481445 @default.
• W4200628818 creator A5044481966 @default.
• W4200628818 creator A5047392421 @default.
• W4200628818 creator A5058317898 @default.
• W4200628818 creator A5063469362 @default.
• W4200628818 creator A5068671845 @default.
• W4200628818 creator A5069896383 @default.
• W4200628818 creator A5084095101 @default.
• W4200628818 date "2021-11-03" @default.
• W4200628818 modified "2023-10-01" @default.
• W4200628818 title "Influence of Plasma Concentration of Hsa-Mir-370-3p and Cyp2d6*4 On Equilibrium Concentration of Phenazepam in Patients with Recurrent Depressive Disorder." @default.
• W4200628818 cites W1742833546 @default.
• W4200628818 cites W1766115599 @default.
• W4200628818 cites W1845447069 @default.
• W4200628818 cites W1984131408 @default.
• W4200628818 cites W2032996390 @default.
• W4200628818 cites W2047705730 @default.
• W4200628818 cites W2082335023 @default.
• W4200628818 cites W2098644261 @default.
• W4200628818 cites W2160070901 @default.
• W4200628818 cites W2165747238 @default.
• W4200628818 cites W2166281097 @default.
• W4200628818 cites W2520356190 @default.
• W4200628818 cites W2619099958 @default.
• W4200628818 cites W2760673365 @default.
• W4200628818 cites W2895937199 @default.
• W4200628818 cites W2898228799 @default.
• W4200628818 cites W2945410001 @default.
• W4200628818 cites W2982634790 @default.
• W4200628818 cites W4232615320 @default.
• W4200628818 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34887601" @default.
• W4200628818 hasPublicationYear "2021" @default.
• W4200628818 type Work @default.
• W4200628818 citedByCount "0" @default.
• W4200628818 crossrefType "journal-article" @default.
• W4200628818 hasAuthorship W4200628818A5010764677 @default.
• W4200628818 hasAuthorship W4200628818A5016233102 @default.
• W4200628818 hasAuthorship W4200628818A5024470067 @default.
• W4200628818 hasAuthorship W4200628818A5025311833 @default.
• W4200628818 hasAuthorship W4200628818A5026059232 @default.
• W4200628818 hasAuthorship W4200628818A5039886441 @default.
• W4200628818 hasAuthorship W4200628818A5040481445 @default.
• W4200628818 hasAuthorship W4200628818A5044481966 @default.
• W4200628818 hasAuthorship W4200628818A5047392421 @default.
• W4200628818 hasAuthorship W4200628818A5058317898 @default.
• W4200628818 hasAuthorship W4200628818A5063469362 @default.
• W4200628818 hasAuthorship W4200628818A5068671845 @default.
• W4200628818 hasAuthorship W4200628818A5069896383 @default.
• W4200628818 hasAuthorship W4200628818A5084095101 @default.
• W4200628818 hasConcept C104317684 @default.
• W4200628818 hasConcept C126322002 @default.
• W4200628818 hasConcept C135763542 @default.
• W4200628818 hasConcept C185592680 @default.
• W4200628818 hasConcept C2779144063 @default.
• W4200628818 hasConcept C2780026642 @default.
• W4200628818 hasConcept C2780035454 @default.
• W4200628818 hasConcept C2780051608 @default.
• W4200628818 hasConcept C2780272996 @default.
• W4200628818 hasConcept C2781413609 @default.
• W4200628818 hasConcept C31467283 @default.
• W4200628818 hasConcept C33664856 @default.
• W4200628818 hasConcept C526171541 @default.
• W4200628818 hasConcept C55493867 @default.
• W4200628818 hasConcept C62231903 @default.
• W4200628818 hasConcept C71924100 @default.
• W4200628818 hasConcept C98274493 @default.
• W4200628818 hasConceptScore W4200628818C104317684 @default.
• W4200628818 hasConceptScore W4200628818C126322002 @default.
• W4200628818 hasConceptScore W4200628818C135763542 @default.
• W4200628818 hasConceptScore W4200628818C185592680 @default.
• W4200628818 hasConceptScore W4200628818C2779144063 @default.
• W4200628818 hasConceptScore W4200628818C2780026642 @default.
• W4200628818 hasConceptScore W4200628818C2780035454 @default.
• W4200628818 hasConceptScore W4200628818C2780051608 @default.
• W4200628818 hasConceptScore W4200628818C2780272996 @default.
• W4200628818 hasConceptScore W4200628818C2781413609 @default.
• W4200628818 hasConceptScore W4200628818C31467283 @default.
• W4200628818 hasConceptScore W4200628818C33664856 @default.
• W4200628818 hasConceptScore W4200628818C526171541 @default.
• W4200628818 hasConceptScore W4200628818C55493867 @default.
• W4200628818 hasConceptScore W4200628818C62231903 @default.
• W4200628818 hasConceptScore W4200628818C71924100 @default.
• W4200628818 hasConceptScore W4200628818C98274493 @default.
• W4200628818 hasIssue "4" @default.
• W4200628818 hasLocation W42006288181 @default.
• W4200628818 hasOpenAccess W4200628818 @default.
• W4200628818 hasPrimaryLocation W42006288181 @default.
• W4200628818 hasRelatedWork W1573559951 @default.
• W4200628818 hasRelatedWork W1982691463 @default.
• W4200628818 hasRelatedWork W1991677481 @default.

• next